OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

Current Rheumatology Reports

, 15:384

Osteopenia: Debates and Dilemmas

  • Jie ZhangAffiliated withDepartment of Epidemiology, University of Alabama at Birmingham
  • , Sarah L. MorganAffiliated withDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham
  • , Kenneth G. SaagAffiliated withDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Whether or not to use pharmacologic agents for primary prevention of fracture among elderly men and women with osteopenia is debated by clinicians. In this review we provide an update to enable better understanding and characterization of this population, including the prevalence of osteopenia, transitioning from osteopenia to osteoporosis, and clinically applicable tools for fracture risk assessment. We also emphasize the very limited evidence of the benefits and risks of anti-osteoporotic agents for this population for primary fracture prevention, and the need for future studies to guide clinical practice.

Keywords

Osteopenia Pharmacologic treatment Debates Epidemiology Fracture risk FRAX Adverse events